Wenchu Lin

Dr. Wenchu Lin

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XWXiaolin Wang
Xiaolin Wang
JLJingxin Li
Jingxin Li
XBXing Bian
Xing Bian
CWCheng Wu
Cheng Wu
JHJinghan Hua
Jinghan Hua
WLWenchu Lin
Wenchu Lin
Significance: Circular RNAs (circRNAs) play increasingly appreciated gene-regulatory roles in the process of human tumorigenesis. Our results demonstrated that circURI1 expression levels were significantly increased in gastric cancer (GC) compared to paraGC, and the depletion of circURI1 promoted metastasis in vitro and in vivo. CircURI1 directly interacted with hnRNPM and modulated alternative splicing by sequestering the hnRNPM protein. Our study provides a reported association of circRNA, alternative splicing, and metastasis and sheds light on the molecular mechanisms of metastatic GC.

25 July 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WLWenchu Lin
Wenchu Lin
JCJian Cao
Jian Cao
JLJiayun Liu
Jiayun Liu
MBMichael L. Beshiri
Michael L. Beshiri
YFYuko Fujiwara
Yuko Fujiwara
Qin YanQin Yan
Qin Yan
Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation ofRbp2decreases tumor formation and prolongs survival inRb1+/−mice andMen1-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy.

6 June 2022 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
JHJinghan Hua
Jinghan Hua
XWXiaolin Wang
Xiaolin Wang
LMLiying Ma
Liying Ma
JLJingxin Li
Jingxin Li
GCGuozhen Cao
Guozhen Cao
WLWenchu Lin
Wenchu Lin
Background: Multiple lines of evidence have demonstrated that circular RNAs (circRNAs) play oncogenic or tumor-suppressive roles in various human cancers. Nevertheless, the biological functions of circRNAs in small cell lung cancer (SCLC) are still elusive. Methods: CircVAPA (annotated as hsa_circ_0006990) was identified by mining the circRNA profiling dataset of six paired SCLC tissues and the RNA-seq data of serum samples from 36 SCLC patients and 118 healthy controls. The circVAPA expression level was evaluated using quantitative real-time PCR in SCLC cells and tissues. Cell viability, colony formation, cell cycle and apoptosis analysis assays and in vivo tumorigenesis were used to reveal the biological roles of circVAPA. The underlying mechanism of circVAPA was investigated by Western blot, RNA pulldown, RNA immunoprecipitation, dual-luciferase reporter assay and rescue experiments. Results: We revealed that circVAPA, derived from exons 2-4 of the vesicle-associated membrane protein-associated protein A (VAPA) gene, exhibited higher expression levels in SCLC cell lines, clinical tissues, and serum from SCLC patients than the controls, and facilitated SCLC progression in vitro and in vivo. Mechanistically, circVAPA activated the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway by modulating the miR-377-3p and miR-494-3p/insulin-like growth factor 1 receptor (IGF1R) axis to accelerate SCLC progression. Furthermore, circVAPA depletion markedly enhanced the inhibitory effects of BMS-536924, an IGF1R kinase inhibitor in cellular and xenograft mouse models. Conclusions: CircVAPA promotes SCLC progression via the miR-377-3p and miR-494-3p/IGF1R/AKT axis. We hope to develop clinical protocols of combinations of circVAPA inhibition and BMS-536924 addition for treating SCLC with circVAPA upregulation.

1 November 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YSYi Sheng
Yi Sheng
WWWei Wang
Wei Wang
BHBo Hong
Bo Hong
XJXingwang Jiang
Xingwang Jiang
RSRuochuan Sun
Ruochuan Sun
YLYongxiang Li
Yongxiang Li
Background: KIF20A is well known as one of the key proteins in mitosis. Recently, a number of studies illustrated that KIF20A might function as an oncogene in some carcinomas. However, its expression levels and clinical value remained unclear in gastric cancer (GC). Patients and methods: In this study, we investigated the expression of KIF20A in samples from GC patients and cell lines by quantitative real-time PCR and Western blot. The function of KIF20A in cell proliferation of GC cell lines was examined via cell viability and colony formation assays. Immunohistochemistry assay based on a tissue microarray consisting of 146 cases was performed to evaluate the prognostic value of KIF20A. The overall survival rate of 122 GC patients based on KIF20A expression was analyzed as well. Finally, using KIF20A inhibitor, genistein, and combining it with cisplatin or fluorouracil, the antitumor effects were studied. Results: Most GC samples (56.76%) showed higher KIF20A expression level compared to their corresponding normal specimens, which demonstrated the potential oncogenic role of KIF20A in GC. The functional studies elucidated the essential role of KIF20A in GC cell proliferation. Besides, tissue microarray result showed that the expression level of KIF20A was significantly related to the histological grades (P=0.036). Furthermore, we found the expression of KIF20A was related to poor overall survival rate, which is coincident with the results from Kaplan–Meier plotter database. In addition, we found that a KIF20A inhibitor, genistein, could enhance the antitumor activity of cisplatin and fluorouracil, which might be considered as a chemosensitive agent in GC. Conclusion: KIF20A can promote cell proliferation in GC, which might be used as an independent prognostic factor and a potential therapeutic target.

4 November 2021 in Bioactive Materials
Verified
Journal Article
Open access
LRLifo Ruan
Lifo Ruan
JCJun Chen
Jun Chen
CDChuanchao Du
Chuanchao Du
HLHuiru Lu
Huiru Lu
JZJiayu Zhang
Jiayu Zhang
YHYi Hu
Yi Hu
Reversal of cancer drug resistance remains a critical challenge in chemotherapy. Mitochondria-targeted drug delivery has been suggested to mitigate drug resistance in cancer. To overcome the intrinsic limitations in conventional mitochondrial targeting strategies, we develop mitochondrial temperature-responsive drug delivery to reverse doxorubicin (DOX) resistance in lung cancer. Results demonstrate that the thermoresponsive nanocarrier can prevent DOX efflux and facilitate DOX accumulation and mitochondrial targeting in DOX-resistant tumors. As a consequence, thermoresponsive nanocarrier enhances the cytotoxicity of DOX and reverses the drug resistance in tumor-bearing mice. This work represents the first example of mitochondrial temperature-responsive drug delivery for reversing cancer drug resistance.

11 July 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XWXiaolin Wang
Xiaolin Wang
JZJiahui Zhang
Jiahui Zhang
GCGuozhen Cao
Guozhen Cao
JHJinghan Hua
Jinghan Hua
GSGe Shan
Ge Shan
WLWenchu Lin
Wenchu Lin
Gastric cancer (GC) is an aggressive malignancy with a high mortality rate and poor prognosis, primarily caused by metastatic lesions. Improved understanding of GC metastasis at the molecular level yields meaningful insights into potential biomarkers and therapeutic targets. Covalently closed circular RNAs (circRNAs) have emerged as crucial regulators in diverse human cancers including GC. Furthermore, accumulating evidence has demonstrated that circRNAs exhibit the dysregulated patterns in GC and have emerged as crucial regulators in GC invasion and metastasis. However, systematic knowledge regarding the involvement of circRNAs in metastatic GC remains obscure. In this review, we outline the functional circRNAs related to GC metastasis and drug resistance and discuss their underlying mechanisms, providing a comprehensive delineation of circRNA functions on metastatic GC and shedding new light on future therapeutic interventions for GC metastases.